Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

fludarabine 63Cyclophosphamide 63venetoclax 58Azacitidine 54fludarabine phosphate 50Specimen Handling 44ruxolitinib 40Whole-Body Irradiation 40Mycophenolic Acid 37Tacrolimus 35Melphalan 32Busulfan 32Biopsy 32Cytarabine 31Decitabine 28Stem Cell Transplantation 27Granulocyte Colony-Stimulating Factor 21Injections 20asciminib 19decitabine and cedazuridine drug combination 18Sirolimus 18Peripheral Blood Stem Cell Transplantation 18Thiotepa 17Filgrastim 17nilotinib 16X-Rays 14Methotrexate 14Imatinib Mesylate 14Cyclosporine 14Magnetic Resonance Spectroscopy 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
tapotoclax × Myeloid × 1 year × Clear all
NCT05209152 2025-07-14

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Amgen

Phase 1 Terminated
7 enrolled 16 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡